Montes Moreno, SantiagoBatlle, AnaGonzález de Villambrosía, SoniaSánchez-Espiridión, BeatrizCereceda, LauraGonzález Barca, EvaPurroy, NoeliaPardal, EmiliaMartín, AlejandroGrande, CarlosMazorra, FranciscoInsunza, AndrésQuero, CristinaAguiar Bujanda, DavidCruz, Miguel ÁngelRueda Dominguez, AntonioLlanos, MartaGómez Codina, JoseGarcía Arroyo, Francisco RamónCaballero, DoloresConde, EulogioLópez, AndresProvencio, MarianoPiris, Miguel A.2020-11-302020-11-302014-08-010390-6078https://hdl.handle.net/2445/172406Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles.4 p.application/pdfeng(c) Ferrata Storti Foundation, 2014QuimioteràpiaLimfomesCèl·lules BDiagnòsticCèl·lules mareChemotherapyLymphomasB cellsDiagnosisStem cellsinfo:eu-repo/semantics/article6798582020-11-30info:eu-repo/semantics/openAccess24763400